Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
| Autor: | Per-Ebbe Jönsson, Bo Nordenskjöld, Göran Landberg, Mårten Fernö, Olle Stål, Monika Dufmats, Ann Christin Källström, Lisa Rydén, Sten Thorstenson, Karin Jirström, Gunilla Chebil |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Breast Neoplasms law.invention Breast cancer Randomized controlled trial law Internal medicine medicine Adjuvant therapy Humans skin and connective tissue diseases Gynecology business.industry Middle Aged Antiestrogen medicine.disease Clinical trial Tamoxifen Premenopause Receptors Estrogen Chemotherapy Adjuvant Relative risk Female business Receptors Progesterone Adjuvant medicine.drug Follow-Up Studies |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 41(2) |
| ISSN: | 0959-8049 |
| Popis: | Adjuvant tamoxifen treatment increases recurrence-free survival (RFS) and overall survival (OS) in early breast cancer, although in premenopausal patients the number of studies comparing tamoxifen vs no treatment are limited. We report herein the effect on RFS of adjuvant tamoxifen treatment in a multicentre trial of premenopausal patients with stage II breast cancer patients randomised between 1986 and 1991 to 2 years of tamoxifen treatment (n = 276) or no treatment (n = 288). The receptor status of the tumour was known for 541 (96%) of the patients included. Tamoxifen treatment significantly increased RFS in patients with hormone receptor-positive (oestrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)) tumours (Relative Risk (RR) 0.65; 95% Confidence Interval (CI): 0.48–0.89, P = 0.006), and the beneficial effect of tamoxifen was extended to patients with indicators of poor prognosis, such as young age and nodal-positivity. PR status was a significant predictor of response to tamoxifen in multivariate models with testing of interactions of hormone receptor status and adjuvant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect